Innate And Adaptive Immunity - USMLE Step 1

SECTION 1

Historical Context & Motivation

The concept that the human body possesses distinct layers of defense against pathogens has evolved over centuries, shaped by observations of disease, vaccination, and the cellular revolution in biology. Long before scientists understood lymphocytes or pattern recognition receptors, physicians recognized that individuals who survived certain infections rarely contracted the same illness again — an observation that hinted at a form of immunological memory. Simultaneously, the rapid inflammatory responses observed at wound sites suggested a fundamentally different, more immediate form of protection. Reconciling these two phenomena — one rapid and nonspecific, the other delayed but highly precise — became one of the central challenges of modern immunology.

1796 • Jenner's Vaccination

Edward Jenner demonstrated that inoculation with cowpox material protected against smallpox, providing the first empirical evidence of adaptive immune memory — even though the underlying mechanisms remained unknown for another century.

1882 • Metchnikoff & Phagocytosis

Élie Metchnikoff observed starfish larvae cells engulfing foreign particles and coined the term phagocytosis, establishing the cellular basis of innate immunity and earning the Nobel Prize in 1908.

1890 • Von Behring & Antitoxins

Emil von Behring and Shibasaburo Kitasato discovered that serum from immunized animals contained antitoxins (antibodies) capable of neutralizing diphtheria toxin, launching the era of humoral immunity research.

1989 • Janeway's Pattern Recognition Hypothesis

Charles Janeway proposed that innate immune cells use germline-encoded pattern recognition receptors (PRRs) to detect conserved microbial structures, bridging innate recognition to adaptive immune activation.

1997 • Discovery of Toll-Like Receptors

Ruslan Medzhitov and Janeway identified the first human Toll-like receptor (TLR), demonstrating that mammalian innate immunity actively senses pathogen-associated molecular patterns (PAMPs). This discovery, later honored with a Nobel Prize to Jules Hoffmann and Bruce Beutler in 2011, unified the field.

These milestones illuminate the central question that this lesson addresses: how does the immune system mount an immediate, broadly effective response to pathogens while simultaneously developing a precise, long-lasting defense against specific threats? The answer lies in the coordinated interplay between innate and adaptive immunity — two arms of host defense that differ in speed, specificity, and memory but are functionally inseparable.

SECTION 2

Core Principles & Definitions

Before dissecting the individual components, it is essential to grasp the foundational principles that distinguish innate from adaptive immunity and explain how they cooperate. Both systems aim to recognize non-self (and sometimes altered-self) molecules while preserving tolerance to healthy host tissues. However, their strategies for recognition, effector function, and long-term protection diverge in critical ways that are heavily tested on USMLE Step 1.

Innate Immunity: First Line

Present from birth and activated within minutes to hours. Uses germline-encoded receptors (PRRs) to recognize conserved pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Lacks immunological memory in the classical sense.

Adaptive Immunity: Precision Strike

Develops over days to weeks upon first encounter (primary response). Relies on somatically rearranged receptors — T-cell receptors (TCRs) and B-cell receptors (BCRs/antibodies) — that confer exquisite antigen specificity. Generates long-lived memory cells for rapid secondary responses.

PAMPs & DAMPs

PAMPs are conserved microbial structures (e.g., LPS, dsRNA, flagellin) recognized by PRRs. DAMPs are endogenous molecules released by damaged or stressed cells (e.g., HMGB1, uric acid). Both trigger innate immune activation and subsequent inflammation.

Bridging: Antigen Presentation

The innate immune system does not merely kill pathogens — it instructs adaptive immunity through antigen-presenting cells (APCs) such as dendritic cells. APCs process pathogen antigens and present them via MHC molecules, providing the critical 'Signal 1' that activates naïve T cells.

Clonal Selection & Memory

Upon antigen recognition, a specific lymphocyte clone expands (clonal expansion), differentiates into effector cells, and generates memory cells. This principle, formulated by Burnet, explains how adaptive immunity becomes faster and stronger with each subsequent exposure to the same antigen.

✦

KEY TAKEAWAY

Think of your immune system as a two-tier security system for a building. Innate immunity is like the locked doors, security cameras, and on-site guards — they respond instantly to any intruder using general protocols but do not 'remember' specific break-in attempts. Adaptive immunity is like a detective unit that takes longer to mobilize but creates a detailed suspect profile, issues arrest warrants (antibodies), and maintains a 'most wanted' database (memory cells) so that the same intruder is caught far more quickly on any future attempt. Crucially, the on-site guards must first alert the detectives — just as innate APCs must activate naïve lymphocytes to launch an adaptive response.

SECTION 3

Visual Overview: Innate vs. Adaptive Immunity

This diagram contrasts the two arms of host defense. The left panel (cyan) represents innate immunity with its physical barriers, cellular components, humoral factors, and PRRs. The right panel (violet) represents adaptive immunity with its T-cell and B-cell branches, antigen-specific receptors, and clonal selection. The golden arrow in the center illustrates the critical bridge: dendritic cells process antigens from the innate response and present them to naïve lymphocytes, initiating the adaptive response.

As illustrated above, the innate immune system provides a rapid, broadly reactive first response through both physical barriers (intact skin, mucosal epithelium, ciliary clearance) and cellular defenders such as neutrophils, macrophages, and natural killer (NK) cells. These cells employ germline-encoded PRRs — including Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors — to detect conserved microbial signatures. The humoral arm of innate immunity includes the complement system, acute-phase proteins such as C-reactive protein, and cytokines like TNF-α and IL-6 that orchestrate inflammation and recruit additional immune cells to the site of infection.

The adaptive immune system, by contrast, requires antigen presentation by innate APCs (primarily dendritic cells) to become activated. Once a naïve T cell recognizes its cognate antigen–MHC complex and receives appropriate costimulatory signals, it undergoes clonal expansion and differentiation into effector subsets. CD4⁺ helper T cells coordinate the immune response through cytokine secretion, while CD8⁺ cytotoxic T cells directly kill infected or abnormal cells. B cells, upon receiving T-cell help, differentiate into antibody-secreting plasma cells. The diversity of antigen receptors — estimated at over 10⁹ unique specificities — is generated by V(D)J recombination during lymphocyte development.

SECTION 4

Mechanistic Deep Dive: Recognition & Activation

Innate Recognition: Pattern Recognition Receptors

The innate immune system relies on a limited set of germline-encoded receptors to detect broad categories of pathogens. These pattern recognition receptors (PRRs) recognize pathogen-associated molecular patterns (PAMPs) — evolutionarily conserved structures that are essential for microbial survival but absent from host cells. Examples include lipopolysaccharide (LPS) on gram-negative bacteria recognized by TLR4, double-stranded RNA from viruses recognized by TLR3, and flagellin recognized by TLR5. Intracellular PRRs such as NLRs detect cytoplasmic threats, while RIG-I and MDA-5 sense intracellular viral RNA.

PRR Family	Location	Ligand (PAMP)	Key Signaling Pathway
TLR4	Cell surface	LPS (Gram-negative bacteria)	MyD88 → NF-κB → TNF-α, IL-1, IL-6
TLR3	Endosomal	dsRNA (viruses)	TRIF → IRF3 → IFN-α/β
TLR9	Endosomal	Unmethylated CpG DNA (bacteria)	MyD88 → NF-κB, IRF7 → IFN-α
NOD2	Cytoplasmic	Muramyl dipeptide (peptidoglycan)	NF-κB → pro-inflammatory cytokines
RIG-I	Cytoplasmic	5′-triphosphate ssRNA (viruses)	MAVS → IRF3/7 → IFN-α/β

Major PRR families and their PAMP ligands — high-yield for USMLE Step 1

Adaptive Recognition: Antigen-Specific Receptors

Adaptive immune recognition is mediated by T-cell receptors (TCRs) and B-cell receptors (BCRs) — both generated through somatic recombination of variable (V), diversity (D), and joining (J) gene segments. This V(D)J recombination process, catalyzed by the RAG-1 and RAG-2 recombinases, generates an enormously diverse receptor repertoire from a limited number of germline gene segments. Additional diversity mechanisms include junctional diversity (N-nucleotide addition by TdT) and, for B cells, somatic hypermutation in germinal centers. A critical distinction is that TCRs recognize processed peptide antigens presented in the groove of MHC molecules (MHC restriction), whereas BCRs/antibodies can bind native, unprocessed antigens directly — including proteins, lipids, carbohydrates, and small molecules.

The Three-Signal Model of T-Cell Activation

Naïve T-cell activation requires three signals, each of which represents a potential point of regulation and clinical intervention. Signal 1 is the antigen-specific signal: the TCR engages a peptide–MHC complex on the APC surface. Signal 2 is costimulation: the interaction between B7 (CD80/CD86) on the APC and CD28 on the T cell is required for full activation; without it, the T cell becomes anergic (functionally unresponsive). Signal 3 consists of polarizing cytokines from the APC (e.g., IL-12 drives Th1 differentiation, IL-4 drives Th2) that determine the effector phenotype of the activated T cell. Notably, CTLA-4 competes with CD28 for B7 binding and delivers an inhibitory signal — a mechanism exploited therapeutically by checkpoint inhibitors such as ipilimumab.

💡

USMLE Pearl

Remember that Signal 1 without Signal 2 = anergy. This is a key mechanism of peripheral tolerance and is frequently tested. Also note: CD4⁺ T cells recognize antigens on MHC class II (found on professional APCs), while CD8⁺ T cells recognize antigens on MHC class I (found on all nucleated cells). Mnemonic: CD4 × MHC II = 8; CD8 × MHC I = 8.

SECTION 5

Detailed Breakdown: Cells & Effector Mechanisms

This timeline flowchart traces the immune response from pathogen entry (left) through innate responses (cyan), the dendritic cell bridge (gold), and adaptive immune activation (violet). Note how CD4⁺ helper T cells drive B-cell activation and class switching, while CD8⁺ cytotoxic T cells directly eliminate infected cells. Both pathways converge on the generation of long-lived memory cells that enable a rapid secondary response upon re-exposure.

Key Innate Immune Cells

Cell Type	Origin / Lineage	Key Functions	Clinical Correlation
Neutrophils	Myeloid; most abundant WBC	Phagocytosis, ROS burst, NETs, first responder to bacterial infection	Chronic granulomatous disease (CGD): defective NADPH oxidase → recurrent catalase⁺ infections
Macrophages	Monocyte-derived; tissue-resident (Kupffer, alveolar, microglia)	Phagocytosis, antigen presentation (MHC II), cytokine secretion, granuloma formation	M1 (pro-inflammatory) vs. M2 (tissue repair) polarization
Dendritic Cells	Myeloid and plasmacytoid subsets	Professional APC; links innate and adaptive immunity; migrates to lymph nodes to activate naïve T cells	Langerhans cells in skin; plasmacytoid DCs produce massive IFN-α in viral infections
NK Cells	Lymphoid lineage (innate lymphoid cell)	Kill virus-infected and tumor cells via perforin/granzyme; ADCC via CD16 (FcγRIII); 'missing-self' hypothesis	Important in early viral defense before adaptive CTLs are generated; Chédiak-Higashi affects NK function
Mast Cells	Myeloid; tissue-resident (skin, mucosa)	Degranulation (histamine, heparin, tryptase); Type I hypersensitivity via IgE-FcεRI cross-linking	Anaphylaxis; allergic rhinitis; mediators cause vasodilation, bronchoconstriction, increased permeability

Summary of key innate immune cell types, their functions, and USMLE-relevant clinical correlations

Key Adaptive Immune Cells

Cell Type	Key Surface Markers	Function	MHC Restriction
CD4⁺ Helper T Cells	TCR, CD3, CD4	Cytokine secretion; direct B-cell help (CD40L); polarize into Th1, Th2, Th17, Tfh, Treg	MHC class II
CD8⁺ Cytotoxic T Cells	TCR, CD3, CD8	Directly kill infected/abnormal cells via perforin/granzyme and Fas/FasL	MHC class I
B Cells / Plasma Cells	BCR (membrane Ig), CD19, CD20; plasma cells: CD138	Antibody production; antigen presentation; class switching; affinity maturation	BCR binds native antigen (no MHC restriction)
Regulatory T Cells (Treg)	CD4, CD25, FoxP3	Suppress immune responses; maintain self-tolerance via IL-10, TGF-β, CTLA-4	MHC class II

Adaptive immune cell types and their key features for USMLE Step 1

SECTION 6

Worked Example: Tracing an Immune Response

Consider the following clinical scenario: a patient sustains a puncture wound from a rusty nail, introducing Staphylococcus aureus into the subcutaneous tissue. The patient has no prior history of staphylococcal infection. Let us trace the sequential activation of innate and adaptive immunity.

Immune Response to Staphylococcus aureus Wound Infection

1
Step 1 — Barrier Breach & Innate Recognition (0–6 hours)

The nail penetrates the skin, disrupting the physical barrier of the epidermis. S. aureus enters the dermis, where tissue-resident macrophages and mast cells recognize bacterial PAMPs. Specifically, peptidoglycan and lipoteichoic acid are detected by TLR2, while bacterial DNA activates TLR9. This triggers intracellular signaling cascades (primarily MyD88 → NF-κB) leading to the release of pro-inflammatory cytokines: TNF-α, IL-1β, and IL-6.

Innate PRR recognition → NF-κB activation → cytokine release → acute inflammation initiated
2
Step 2 — Neutrophil Recruitment & Acute Inflammation (6–24 hours)

TNF-α and IL-1 upregulate E-selectin and ICAM-1 on local vascular endothelium. Circulating neutrophils undergo the multi-step adhesion cascade: rolling (selectins), tight adhesion (integrins LFA-1/ICAM-1), diapedesis, and chemotaxis toward IL-8 (CXCL8) gradients. Neutrophils phagocytose bacteria using opsonins (C3b, IgG if pre-existing) and kill them via the respiratory burst (NADPH oxidase → superoxide → H₂O₂ + Cl⁻ → HOCl via myeloperoxidase). The complement cascade is simultaneously activated through the alternative pathway (C3 tickover → C3b deposits on bacterial surface), generating C3a and C5a anaphylatoxins that further recruit inflammatory cells.

Massive neutrophil influx → phagocytosis and bacterial killing → pus formation at wound site
3
Step 3 — Dendritic Cell Activation & Antigen Transport (12–48 hours)

Immature dendritic cells (DCs) in the dermis phagocytose bacteria and bacterial debris. PAMP-induced TLR signaling triggers DC maturation: they upregulate MHC class II, B7 costimulatory molecules (CD80/CD86), and CCR7. The chemokine receptor CCR7 directs the now-mature DCs to migrate via afferent lymphatics to the draining lymph node, where they will encounter naïve T cells in the paracortical zone.

Mature DC migrates to lymph node bearing processed staphylococcal peptides on MHC II — bridge to adaptive immunity
4
Step 4 — T-Cell Activation & Clonal Expansion (4–7 days)

In the paracortical zone, the mature DC presents staphylococcal peptide–MHC II complexes to naïve CD4⁺ T cells. A naïve T cell whose TCR has sufficient affinity for this complex receives Signal 1. Simultaneously, B7–CD28 interaction delivers Signal 2 (costimulation). The DC secretes IL-12 (Signal 3), which drives differentiation toward a Th1 phenotype. The activated Th1 cell undergoes clonal expansion over several days, producing large numbers of effector cells that secrete IFN-γ. IFN-γ activates macrophages (classical activation / M1 polarization), dramatically enhancing their bactericidal capacity. Meanwhile, some activated CD4⁺ T cells differentiate into T follicular helper (Tfh) cells that migrate to B-cell follicles to provide help for antibody production.

Th1 clonal expansion → IFN-γ → macrophage activation; Tfh cells → B-cell help in germinal centers
5
Step 5 — B-Cell Response, Antibody Production & Memory (7–14+ days)

B cells in the lymph node cortex that have bound staphylococcal antigen via their BCR internalize, process, and present it on MHC II to Tfh cells. The Tfh cell delivers help via CD40L–CD40 interaction and IL-21 secretion. This T-dependent activation triggers B-cell proliferation, class switching from IgM to IgG (and potentially IgA), and somatic hypermutation with affinity maturation in germinal centers. High-affinity plasma cells are selected, exit the germinal center, and produce large quantities of anti-staphylococcal IgG that opsonizes bacteria for enhanced phagocytosis. Long-lived memory B cells and memory T cells are generated, residing in lymphoid tissues and bone marrow respectively. Upon future encounters with S. aureus, these memory cells will mount a faster (within 1–3 days), higher-affinity secondary response.

Pathogen cleared; high-affinity IgG antibodies produced; memory cells established for rapid secondary response

SECTION 7

Innate vs. Adaptive: Comprehensive Comparison

Understanding the distinctions between innate and adaptive immunity is among the most frequently tested concepts on USMLE Step 1. While both systems collaborate to protect the host, their mechanisms of recognition, timing, specificity, and capacity for memory diverge in clinically relevant ways. The following comparison table consolidates these differences across multiple dimensions.

Feature	Innate Immunity	Adaptive Immunity
Response time	Minutes to hours (immediate)	Days to weeks (primary); hours to days (secondary)
Specificity	Broad; recognizes conserved PAMPs shared by microbial classes	Highly specific; recognizes unique epitopes via TCR/BCR
Receptor diversity	Limited (~100 PRRs); germline-encoded; identical on all cells of a type	>10⁹ unique receptors; generated by V(D)J recombination; each lymphocyte has a unique receptor
Memory	No classical memory (some 'trained immunity' via epigenetic reprogramming of monocytes)	Robust immunological memory; memory T and B cells enable faster, stronger secondary responses
Self vs. non-self	Distinguishes via PRRs (PAMPs absent from host) and 'missing-self' (NK cells)	Central tolerance (thymus/bone marrow deletion) and peripheral tolerance (anergy, Tregs, deletion)
Key cells	Neutrophils, macrophages, DCs, NK cells, mast cells, eosinophils, basophils	CD4⁺ T cells, CD8⁺ T cells, B cells / plasma cells
Humoral components	Complement, lysozyme, defensins, acute-phase proteins, cytokines (TNF-α, IL-1, IL-6, IFN-α/β)	Antibodies (IgG, IgA, IgM, IgE, IgD), cytokines (IL-2, IL-4, IL-5, IFN-γ, IL-17)
Improves with exposure	No (response is qualitatively similar each time)	Yes — affinity maturation, class switching, and expanded memory pool
Physical barriers	Yes — skin, mucosal surfaces, cilia, acid pH, commensal flora	No (purely cellular and humoral)

Comprehensive comparison of innate and adaptive immunity

⚕

CLINICAL INTEGRATION

Many immunodeficiency disorders can be categorized by which arm they impair. Defects in innate immunity (e.g., chronic granulomatous disease — NADPH oxidase deficiency, or leukocyte adhesion deficiency — defective integrins) typically present with recurrent bacterial and fungal infections from early life. Defects in adaptive immunity (e.g., X-linked agammaglobulinemia — absent B cells due to BTK mutation, or DiGeorge syndrome — absent thymus, T-cell deficiency) present with susceptibility to specific pathogen classes (encapsulated bacteria in antibody deficiency; viral and fungal infections in T-cell deficiency). SCID (severe combined immunodeficiency) affects both T and B cell function and is the most severe form, presenting within the first months of life with opportunistic infections.

SECTION 8

Connection to Advanced Immunological Concepts

The classical dichotomy between innate and adaptive immunity, while foundational, becomes increasingly nuanced as you progress through immunology. Several advanced concepts blur the boundaries between these two systems, and understanding these connections will strengthen both your Step 1 performance and your preparation for clinical reasoning.

Foundational Concept	Advanced Extension	Clinical Relevance
Innate immunity lacks memory	Trained immunity: Monocytes/macrophages exposed to β-glucan or BCG undergo epigenetic reprogramming (H3K4me3 at pro-inflammatory gene loci), producing enhanced responses to subsequent unrelated pathogens	May explain non-specific protective effects of BCG vaccination against non-TB infections; implications for vaccine adjuvant design
NK cells are purely innate	NK cell memory: CMV-specific NK cells expressing NKG2C undergo clonal-like expansion and persist as long-lived memory-like cells	Blurs the innate/adaptive boundary; potential for NK-cell-based immunotherapies
T cells are adaptive only	γδ T cells and NKT cells: These unconventional lymphocytes use limited receptor diversity, recognize non-peptide antigens (lipids via CD1, phosphoantigens), and respond rapidly without prior priming	γδ T cells are abundant in mucosal tissues; NKT cells bridge innate and adaptive in anti-tumor immunity
Complement is innate only	Classical complement pathway: Activated by IgG and IgM immune complexes, making complement a key effector mechanism of adaptive humoral immunity	Type II and III hypersensitivity reactions; complement deficiencies (C1q, C2, C4) → SLE-like syndrome due to impaired immune complex clearance
Checkpoint inhibitors target adaptive immunity	Innate immune checkpoints: CD47-SIRPα ('don't eat me' signal) on tumor cells inhibits macrophage phagocytosis; anti-CD47 therapies are in clinical trials	Expanding immunotherapy beyond T-cell checkpoints (CTLA-4, PD-1) to innate immune modulation

Advanced concepts that bridge or expand the innate-adaptive dichotomy

These advanced concepts underscore a crucial principle: the innate and adaptive immune systems are not independent silos but rather a deeply interconnected network with overlapping features. For Step 1, focus on the classical distinctions while recognizing that exceptions like trained immunity, NK cell memory, and γδ T cells represent the evolving frontier of immunology. These topics are increasingly appearing in USMLE questions that test deeper understanding.

ℹ

Looking Ahead

As you progress through the immunology curriculum, these concepts will connect to major clinical areas: hypersensitivity reactions (Types I–IV), autoimmunity (breakdown of self-tolerance), immunodeficiencies (innate vs. adaptive defects), transplant immunology (graft rejection mechanisms), and tumor immunology (immune surveillance and evasion). Each of these topics builds directly on your understanding of innate and adaptive immunity.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A researcher isolates two types of immune cells from a patient. Cell type A responds identically to Escherichia coli and Salmonella typhimurium infections with similar kinetics, while Cell type B responds specifically to E. coli but not Salmonella, and the response is stronger upon second exposure to E. coli. Which cell type belongs to the innate immune system, and what feature of Cell type B most clearly distinguishes it as adaptive?

Show answer

Cell type A belongs to the innate immune system because it responds to both gram-negative bacteria with similar speed and intensity, reflecting broad specificity mediated by PRRs (likely TLR4 detecting LPS common to both organisms). Cell type B is an adaptive immune cell because it demonstrates two hallmark features: (1) antigen specificity — it distinguishes between E. coli and Salmonella, and (2) immunological memory — the enhanced secondary response indicates memory cell formation and clonal expansion from a previous encounter. The most distinguishing feature is memory, as it is uniquely characteristic of adaptive immunity.

Question 2: BASIC CALCULATION

The human genome contains approximately 200 V gene segments, 30 D segments, and 6 J segments for the immunoglobulin heavy chain. If receptor diversity were generated solely by combinatorial joining of V, D, and J segments (ignoring junctional diversity, light chain pairing, and somatic hypermutation), how many unique heavy chain variable regions could be produced? How does this compare to the estimated total T-cell and B-cell receptor diversity of >10⁹?

Show answer

Combinatorial diversity of the heavy chain is calculated as V × D × J = 200 × 30 × 6 = 36,000 unique heavy chain combinations. This is substantial but falls far short of 10⁹. The enormous gap is bridged by additional diversity mechanisms: (1) junctional diversity (N-nucleotide addition by TdT and P-nucleotide addition at V-D and D-J junctions), (2) combinatorial pairing of heavy and light chains (each light chain has its own V-J recombination, yielding ~320 κ and ~200 λ combinations), and (3) for B cells, somatic hypermutation in germinal centers that introduces point mutations into variable regions. These additional mechanisms collectively amplify diversity from ~10⁴ combinatorial possibilities to >10⁹ unique receptors.

Question 3: INTERMEDIATE

A 2-year-old boy presents with recurrent pyogenic infections caused by Staphylococcus aureus and Aspergillus species. Nitroblue tetrazolium (NBT) testing reveals absent color change, and dihydrorhodamine (DHR) flow cytometry shows no fluorescent shift. Serum immunoglobulin levels and lymphocyte subsets are normal. Which arm of immunity is defective? Identify the specific molecular defect and explain why this patient is particularly susceptible to catalase-positive organisms.

Show answer

This presentation is classic for chronic granulomatous disease (CGD), a defect of innate immunity. The molecular defect is in the NADPH oxidase complex (most commonly the gp91-phox subunit in X-linked CGD), which is responsible for generating superoxide (O₂⁻) during the respiratory burst in neutrophils and macrophages. The absent NBT reduction and DHR fluorescence confirm the inability to produce reactive oxygen species. The patient is susceptible to catalase-positive organisms (S. aureus, Aspergillus, Serratia, Nocardia, Burkholderia — mnemonic: 'Cats Need PLACEMENTS') because catalase-negative bacteria (like Streptococcus) produce their own H₂O₂, which the phagocyte can use via myeloperoxidase even without a functional oxidase. Catalase-positive organisms destroy this 'donated' H₂O₂, leaving the CGD phagocyte with no oxidative killing mechanism. Normal immunoglobulin levels confirm intact adaptive humoral immunity.

Question 4: APPLIED

A pharmaceutical company develops a new vaccine using a purified polysaccharide capsular antigen from Streptococcus pneumoniae. In clinical trials, the vaccine generates protective IgM antibodies in adults but fails to produce IgG antibodies or long-term protection. The vaccine is also ineffective in children under 2 years old. Explain the immunological basis for these observations and propose a modification to improve the vaccine.

Show answer

Polysaccharide antigens are T-independent antigens because they cannot be processed and presented on MHC class II (which presents peptides, not carbohydrates). Without T-cell help, B cells are activated through cross-linking of surface IgM by repetitive polysaccharide epitopes, producing an IgM-dominated response with limited class switching to IgG and no generation of memory B cells — explaining the lack of long-term protection. The failure in children under 2 reflects the immaturity of marginal zone B cells (the primary responders to T-independent antigens) in early life. The modification is to create a conjugate vaccine by covalently linking the polysaccharide to a protein carrier (e.g., diphtheria toxoid, as in Prevnar-13/PCV13). The protein carrier is processed by B cells and presented on MHC II to Tfh cells, converting the response from T-independent to T-dependent. This enables class switching (IgM → IgG), affinity maturation, and robust immunological memory, effective even in infants.

Question 5: CRITICAL THINKING

A patient with metastatic melanoma is treated with ipilimumab (anti-CTLA-4) and subsequently develops severe colitis and hepatitis. Explain the immunological mechanism by which ipilimumab exerts its anti-tumor effect and why these autoimmune-like adverse effects are a predictable consequence of the drug's mechanism. How does this scenario illustrate the fundamental relationship between immune activation and self-tolerance, connecting both innate and adaptive immune principles discussed in this lesson?

Show answer

Ipilimumab is a monoclonal antibody that blocks CTLA-4, a negative regulator (immune checkpoint) expressed on activated T cells. Normally, CTLA-4 competes with CD28 for binding to B7 (CD80/CD86) on APCs, delivering an inhibitory signal that dampens T-cell activation — a critical mechanism of peripheral tolerance. By blocking CTLA-4, ipilimumab removes this 'brake,' resulting in enhanced and prolonged T-cell activation, including activation of tumor-specific CD8⁺ cytotoxic T cells that can now mount an effective anti-tumor response. However, this same uninhibited activation extends to T cells reactive against self-antigens that would normally be suppressed by CTLA-4-mediated regulation. The result is immune-related adverse events (irAEs) — autoimmune colitis, hepatitis, dermatitis, and endocrinopathies — that are a direct, predictable consequence of broadly removing immune suppression. This scenario beautifully illustrates the innate-adaptive axis: the initial anti-tumor immune response depends on dendritic cells (innate) processing tumor antigens and presenting them to T cells (adaptive) in the context of appropriate costimulation. The balance between immune activation (eliminating threats) and self-tolerance (preventing autoimmunity) is maintained by checkpoints like CTLA-4 and regulatory T cells. Disrupting this balance therapeutically reveals that the same immune mechanisms that protect against pathogens and tumors can, without proper regulation, attack the host — the fundamental tension at the heart of immunology.

SUMMARY

Summary: Innate and Adaptive Immunity

Summary

The immune system operates through two interdependent arms. Innate immunity provides immediate, broadly reactive defense through physical barriers (skin, mucosa), cellular effectors (neutrophils, macrophages, NK cells, dendritic cells, mast cells), and humoral factors (complement, cytokines, acute-phase proteins). These components use germline-encoded pattern recognition receptors (PRRs) — including TLRs, NLRs, and RIG-I — to detect conserved PAMPs and DAMPs, activating inflammation within minutes to hours without generating classical immunological memory.

Adaptive immunity develops over days to weeks and is characterized by antigen specificity (via somatically rearranged TCRs and BCRs produced by V(D)J recombination) and immunological memory (via long-lived memory T and B cells). CD4⁺ helper T cells coordinate the immune response through cytokine secretion and B-cell help (MHC class II restricted), while CD8⁺ cytotoxic T cells kill infected cells via perforin/granzyme (MHC class I restricted). B cells differentiate into plasma cells producing antibodies that neutralize, opsonize, and activate complement. The critical bridge between the two systems is antigen presentation by dendritic cells, which process pathogen antigens and deliver the three signals (antigen-MHC, costimulation, polarizing cytokines) required for naïve T-cell activation. Understanding the interplay between these two arms — and the clinical consequences of their dysfunction — is foundational for USMLE Step 1 success across immunology, microbiology, and pathology.